Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Promising Nephrotic Syndrome Treatments: A Look into the Future
Nephrotic syndrome is a clinical condition characterized by significant protein in the urine (exceeding 40 mg/m2/h), leading to low levels of albumin (below 30 g/L), which in turn causes high levels of lipids, swelling, and a range of associated complications. The epidemiological assessment of nephrotic syndrome plays a pivotal role in understanding the prevalence, distribution, and impact of this renal disorder. To comprehensively evaluate the landscape of nephrotic syndrome, assumptions, and rationales are employed to delineate the primary and secondary glomeruli nephropathies contributing to the overall burden of the syndrome.…
Unveiling the Potential of TROP-2 Inhibitors: A New Frontier in Cancer Treatment
Trophoblast cell surface antigen-2 (TROP-2) is a 35-kDa protein found on cell membranes, made of sugars and a protein chain, serving as a transmitter of calcium signals. It is produced by the TACSTD2 gene and shares a structural similarity with the epithelial cell adhesion molecule (EpCAM). TROP2, although identified for its promising potential in cancer treatment some years ago, is now emerging as a significant protein target. With the rise of targeted therapies and immunotherapies, TROP2 has gained attention due to its crucial role in cancer cell proliferation and spread.…
Allumiqs and Prolytix’s Partnership; Setpoint Medical’s Neuroimmune Modulation Platform gets FDA Breakthrough Designation; MangoRx Launches ‘PRIME’ with FDA-approved TRT; SeaStar Medical Updates Quelimmune Commercial Launch; Ventris Medical Gains 510(k) for Amplify® Bone Graft Putty
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment On March 12, 2024, Mangoceuticals, Inc. unveiled a groundbreaking development eagerly awaited by many: the launch of 'PRIME' by MangoRx, Powered by Kyzatrex®️. This release marks a significant milestone as it introduces FDA-approved oral Testosterone Replacement Therapy (TRT) to a broad consumer base throughout the United States. By leveraging its innovative telehealth platform, Mangoceuticals aims to make this transformative treatment easily accessible to individuals seeking effective Testosterone Replacement Therapy solutions. MangoRx plans to…